Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun;31(6):2391-2400.
doi: 10.1007/s11695-021-05280-6. Epub 2021 Feb 27.

Bariatric-Metabolic Surgery Utilisation in Patients With and Without Diabetes: Data from the IFSO Global Registry 2015-2018

Richard Welbourn  1 , Marianne Hollyman  2 , Robin Kinsman  3 , John Dixon  4 , Ricardo Cohen  5 , John Morton  6 , Amir Ghaferi  7 , Kelvin Higa  8 , Johan Ottosson  9 , Francois Pattou  10 , Salman Al-Sabah  11 , Merhan Anvari  12 , Jacques Himpens  13 , Ronald Liem  14 , Villy Våge  15 , Peter Walton  3 , Wendy Brown  16 , Lilian Kow  17
Affiliations

Bariatric-Metabolic Surgery Utilisation in Patients With and Without Diabetes: Data from the IFSO Global Registry 2015-2018

Richard Welbourn et al. Obes Surg. 2021 Jun.

Abstract

Background: Comparative international practice of patients undergoing bariatric-metabolic surgery for type 2 diabetes mellitus (T2DM) is unknown. We aimed to ascertain baseline age, sex, body mass index (BMI) and types of operations performed for patients with T2DM submitted to the IFSO Global Registry.

Materials and methods: Cross-sectional analysis of patients having primary surgery in 2015-2018 for countries with ≥90% T2DM data completion and ≥ 1000 submitted records.

Results: Fifteen countries including 11 national registries met the inclusion criteria. The rate of T2DM was 24.2% (99,537 of 411,581 patients, country range 12.0-55.1%) and 77.1% of all patients were women. In every country, patients with T2DM were older than those without T2DM (overall mean age 49.2 [SD 11.4] years vs 41.8 [11.9] years, all p < 0.001). Men were more likely to have T2DM than women, odds ratio (OR) 1.68 (95% CI 1.65-1.71), p < 0.001. Men showed higher rates of T2DM for BMI <35 kg/m2 compared to BMI ≥35.0 kg/m2, OR 2.76 (2.52-3.03), p < 0.001. This was not seen in women, OR 0.78 (0.73-0.83), p < 0.001. Sleeve gastrectomy was the commonest operation overall, but less frequent for patients with T2DM, patients with T2DM 54.9% vs without T2DM 65.8%, OR 0.63 (0.63-0.64), p < 0.001. Twelve out of 15 countries had higher proportions of gastric bypass compared to non-bypass operations for T2DM, OR 1.70 (1.67-1.72), p < 0.001.

Conclusion: Patients with T2DM had different characteristics to those without T2DM. Older men were more likely to have T2DM, with higher rates of BMI <35 kg/m2 and increased likelihood of food rerouting operations.

Keywords: Bariatric surgery; Comorbidity; Demographic classification; IFSO Global Registry; Metabolic surgery; Obesity surgery; Operation choice for diabetes; Sex characteristics; Type 2 diabetes.

PubMed Disclaimer

Conflict of interest statement

Dr Welbourn reports personal fees from Novo Nordisk, outside the submitted work.

Drs Kinsman and Walton report grants from IFSO, outside the submitted work.

Dr Dixon reports personal fees from NHMRC, during the conduct of the study; personal fees from Reshape, personal fees from Bariatric Advantage, personal fees from Novo Nordisk, personal fees from Nestle Health Science, personal fees from Johnson & Johnson, and personal feed from I-Nova, outside the submitted work.

Dr Cohen reports personal fees from GI Dynamics, grants from Johnson & Johnson Medical, Brazil, outside the submitted work.

Dr Ottosson reports consultancy fees from Johnson & Johnson and Vifor Pharma, outside the submitted work.

Dr Anvari reports consultancy fees from Johnson & Johnson, outside the submitted work.

Dr Himpens reports personal fees from Ethicon, personal fees from Medtronic, outside the submitted work.

Dr Brown reports grants from Johnson and Johnson, grants from Medtronic, grants from GORE, personal fees from GORE, grants from Applied Medical, grants from Apollo Endosurgery, grants and personal fees from Novo Nordisk, personal fees from Merck Sharpe and Dohme, outside the submitted work; and I am a bariatric surgeon so earn my living from performing these procedures.

Drs Hollyman, Morton, Ghaferi, Higa, Pattou, Al-Sabah, Liem, Våge, Kow have nothing to disclose.

Figures

Fig. 1
Fig. 1
Primary surgery: male and female patients on medication for T2DM prior to surgery and initial BMI; calendar years 2015–2018. Data are rates (error bars 95% CI) ordered by increasing rate of T2DM per country for BMI range 35.0–39.9 kg/m2 in women. T2DM, type 2 diabetes mellitus; BMI, body mass index
Fig. 2
Fig. 2
T2DM rates for adult men and women in the general adult (age ≥ 18 years) population from NCD-RisC, calendar year 2014, versus the rate for patients on medication for T2DM undergoing primary bariatric surgery, calendar years 2015–2018. Oblique line represents parity for general adult population prevalence of T2DM and proportion of operated patients on medication for T2DM. T2DM, type 2 diabetes mellitus; NCD-RisC, Non-Communicable Diseases Risk Factor Collaboration; AUT, Austria; BHR, Bahrain; BRA, Brazil; EGY, Egypt; FRA, France; IND, India; ISR, Israel; KWT, Kuwait; QAT, Qatar; RUS, Russia; SWE, Sweden; ARE, United Arab Emirates; GBR, United Kingdom; USA, United States of America
Fig. 3
Fig. 3
Primary surgery: type of operation performed for patients with or without medication for T2DM pre-operatively; calendar years 2015–2018, ordered by increasing rate of SG for patients without medication for T2DM. Data are rates (error bars 95% CI). T2DM, type 2 diabetes mellitus; SG, sleeve gastrectomy
See this image and copyright information in PMC

Comment in

References

    1. Cheng J, Gao J, Shuai X, et al. The comprehensive summary of surgical versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomized controlled trials. Oncotarget. 2016;7(26):39216–30. 10.18632/oncotarget.9581. - PMC - PubMed
    1. Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. NEJM. 2017;376:641–51. 10.1056/NEJMoa1600869. - PMC - PubMed
    1. Salminen P, Helmiö M, Ovaska J, et al. Effect of laparoscopic sleeve gastrectomy vs laparoscopic Roux-en-Y gastric bypass on weight loss at 5 years among patients with morbid obesity: the SLEEVEPASS randomized clinical trial. JAMA. 2018;319(3):241–54. - PMC - PubMed
    1. Peterli R, Wölnerhanssen BK, Peters T, et al. Effect of laparoscopic sleeve gastrectomy vs laparoscopic Roux-en-Y gastric bypass on weight loss in patients with morbid obesity: the SM-BOSS randomized clinical trial. JAMA. 2018;319(3):255–65. 10.1001/jama.2017.20897. - PMC - PubMed
    1. Hofsø D, Fatima F, Borgeraas H, et al. Gastric bypass versus sleeve gastrectomy in patients with type 2 diabetes (Oseberg): a singlecenter, triple-blind, randomized controlled trial. Lancet Diabetes Endocrinol. 2019;7(12):912–24. - PubMed

Publication types